2016 - Elise Aasebø
Born 1986, holds an M.S. in Medical Cell Biology from UiB. As a PhD candidate, she was in the acute myeloid leukemia (AML) group at PROBE and connected to the Gjertsen group at CCBIO. She applied quantitative mass spectrometry-based proteomics on AML cells, with the aim to identify biomarkers which could improve prognostication of AML patients.
Main content
Elise Aasebø defended Friday November 4th 2016 her thesis: “Mass spectrometry-based proteome quantification in leukemic cells from acute myeloid leukemia patients” at the University of Bergen. Frode S. Berven was main supervisor, with Frode Selheim, Marc Vaudel and Bjørn Tore Gjertsen as co-supervisors. See press release.
Read more about the Gjertsen group and about PROBE.
30.10.2017